Department of Ophthalmology, Dongguk University, Ilsan Hospital, Goyang, South Korea.
School of Chemical Engineering and Material Science, Chung-Ang University, Seoul, South Korea.
Sci Rep. 2017 Aug 15;7(1):8238. doi: 10.1038/s41598-017-08843-9.
Nonporous silica nanoparticles (SiNPs) have potential as promising carriers for ophthalmic drugs. However, the in vivo safety of ocular topical SiNPs remains unclear. This study investigated the in vivo safety of oral and ocular topical applications of 100 nm-sized SiNPs in Sprague-Dawley rats. The rats were divided into the following four groups: low-dose oral administration (total 100 mg/kg of SiNPs mixed with food for one week), high-dose oral administration (total 1000 mg/kg of SiNPs mixed with food for one week), ocular topical administration (10 mg/ml concentration, one drop, applied to the right eyes four times a day for one month), or a negative control (no SiNP treatment). The rats were observed for 12 weeks to investigate any signs of general or ocular toxicity. During the observation period, no differences were observed in the body weights, food and water intakes, behaviors and abnormal symptoms of the four groups. No animal deaths occurred. After 12 weeks, hematologic, blood biochemical parameters and ophthalmic examinations revealed no abnormal findings in any of the animals. The lack of toxicity of the SiNPs was further verified in autopsy findings of brain, liver, lung, spleen, heart, kidneys, intestine, eyeballs, and ovaries or testes.
无孔硅纳米颗粒(SiNPs)有望成为眼科药物的理想载体。然而,眼部局部应用 SiNPs 的体内安全性尚不清楚。本研究探讨了口服和眼部局部应用 100nm 大小的 SiNPs 在 Sprague-Dawley 大鼠体内的安全性。大鼠分为以下四组:低剂量口服给药(总剂量为 100mg/kg 的 SiNPs 与食物混合,持续一周)、高剂量口服给药(总剂量为 1000mg/kg 的 SiNPs 与食物混合,持续一周)、眼部局部给药(浓度为 10mg/ml,右眼滴一滴,每天四次,持续一个月)或阴性对照(无 SiNP 处理)。观察大鼠 12 周,以研究任何全身或眼部毒性的迹象。在观察期间,四组大鼠的体重、食物和水的摄入量、行为和异常症状均无差异。没有动物死亡。12 周后,血液学、血液生化参数和眼科检查显示所有动物均无异常发现。SiNPs 的无毒作用进一步通过大脑、肝脏、肺、脾、心脏、肾脏、肠、眼球以及卵巢或睾丸的尸检结果得到证实。